Acadia Healthcare Company, Inc. (ACHC) SEC Filings & Earnings Calls
EquiReason read 20 Acadia Healthcare Company, Inc. SEC filings in the last 12 months. Latest: 8-K on 2026-09-25 — Acadia Healthcare disclosed preliminary approval of a settlement in stockholder derivative actions related to previously settled securities litigation. The settlement is subject to.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 2.9B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
25 Sep 20268-K · 8.01Acadia Healthcare disclosed preliminary approval of a settlement in stockholder derivative actions related to previously settled securities litigation. The settlement is subject to final court approval.open
Risks flagged
Settlement of derivative litigation may involve governance changes or costs, but terms not disclosed.
“Stipulation of Settlement dated July 31, 2026” · word for word
28 Jul 20268-K · 2.02, 7.01Revenue $866M (+0% y/y); Adjusted EBITDA $149M (-26% y/y); Adjusted EPS $0.38 (-54% y/y); Guidance: Full year 2026 financial and cash flow guidance updated downwardearningsopen
Figures in the filing · each found in the filing text
| Revenue · Q2-2026 | $866M | 0% y/y |
| Adjusted EBITDA · Q2-2026 | $149M | -26% y/y |
| Adjusted EPS · Q2-2026 | $0.38 | -54% y/y |
| Same-facility patient days growth · Q2-2026 | 0.8% | |
| Same-facility revenue per patient day growth · Q2-2026 | -0.8% | |
| Operating cash flow · Q2-2026 | $162M | +21% y/y |
| Capital expenditures · Q2-2026 | $39M | -77% y/y |
| Licensed beds added · Q2-2026 | 240 |
Guidance
Full year 2026 financial and cash flow guidance updated downward
Full year 2026 guidance cut; management tone positive citing operational execution and capacity expansion.
Risks flagged
Legal reserve adjustment of $28.6M significantly impacted earnings; potential for further adjustments.
“$28.6 million adjustment to professional and general liability reserves.” · word for word
Revenue flat despite capacity expansion; supplemental payment program timing creates volatility.
“Total revenue flat YoY; normalized growth 2.8% after adjusting for supplemental payments.”
28 Jul 202610-QAcadia Healthcare reported Q2 2026 revenue decline and significant net income drop due to labor cost pressure and higher operating expenses.earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q2-2026 | $866M | -0% y/y |
| Net income attributable to Acadia Healthcare Company, Inc. · Q2-2026 | $11M | -64% y/y |
| Same facility revenue growth · Q2-2026 | -0.1% | |
| Same facility patient days growth · Q2-2026 | 0.8% | |
| Same facility admissions growth · Q2-2026 | 6.4% | |
| Same facility average length of stay change · Q2-2026 | -5.3% | |
| Same facility revenue per patient day growth · Q2-2026 | -0.8% | |
| Salaries, wages and benefits as % of revenue · Q2-2026 | 54.8% | |
| Other operating expenses as % of revenue · Q2-2026 | 18.0% | |
| Bed count · 2026-06-30 | 12,600 |
Risks flagged
Medicaid reimbursement risk
“The OBBBA reduces the federal government’s overall Medicaid expenditures and tightens Medicaid eligibility requirements.” · word for word
Labor cost pressure
“Similar to many other healthcare providers and other industries across the country, we have been navigating a tight labor market.” · word for word
Legal and regulatory risk
“Government investigations include legal fees and settlement costs related to certain litigation, including the matters referenced in Note 8 – Commitments and Contingencies in the accompanying notes to our condensed consolidated financial statements.” · word for word
18 May 20268-K · 8.01Disclosed a material event under other events (litigation, recall, contract loss, or major announcement)open
Risks flagged
Jury verdict of $105M in employment lawsuit; company intends to appeal but outcome uncertain.
“Jury awarded $35M compensatory and $70M punitive damages.”
30 Apr 202610-QRevenue $829M (+8% y/y); Net income attributable to Acadia Healthcare Company, Inc. $4M (-51% y/y); Operating cash flow $62M (+435% y/y)open
Figures in the filing · each found in the filing text
| Revenue · Q1-2026 | $829M | +8% y/y |
| Net income attributable to Acadia Healthcare Company, Inc. · Q1-2026 | $4M | -51% y/y |
| Operating cash flow · Q1-2026 | $62M | +435% y/y |
| Bed count · 2026-03-31 | 12,400 | |
| Facility count · 2026-03-31 | 275 | |
| Cash and cash equivalents · 2026-03-31 | $159M | |
| Same facility revenue growth · Q1-2026 | 7.3% | |
| Same facility patient days growth · Q1-2026 | 1.6% | |
| Same facility admissions growth · Q1-2026 | 6.5% | |
| Same facility average length of stay change · Q1-2026 | -4.6% |
Risks flagged
Medicaid reimbursement reduction from OBBBA
“The OBBBA reduces the federal government’s overall Medicaid expenditures and tightens Medicaid eligibility requirements.” · word for word
Elevated legal and investigation costs
“Government investigations include legal fees and settlement costs related to certain litigation, including the matters referenced in Note 8 — Commitments and Contingencies.” · word for word
Labor cost inflation
“Salaries, wages and benefits expense was $467.0 million for the three months ended March 31, 2026 compared to $445.3 million for the three months ended March 31, 2025, an increase of $21.7 million.”
High leverage and interest expense
“Interest expense was $38.3 million for the three months ended March 31, 2026 compared to $29.2 million for the three months ended March 31, 2025. The increase in interest expense was primarily the result of increased borrowings.” · word for word
29 Apr 20268-K · 2.02, 7.01Released earnings results and quarterly financials; issued a Regulation FD disclosure (forward guidance or material update)earningsopen
Risks flagged
Regulatory risk from OBBBA Medicaid changes
“Risk factor mentions OBBBA enacted July 4, 2025, introducing work requirements in Medicaid expansion population”
Labor cost pressure
“Risk factor mentions increased costs relating to labor”
23 Apr 20268-K · 5.02, 7.01Base salary $100,000.00; quarterly cash bonus $125,000.00; severance payment $350,000.00open
Figures in the filing · each found in the filing text
| base salary · point_in_time | $100000.00 | |
| quarterly cash bonus · point_in_time | $125000.00 | |
| severance payment · point_in_time | $350000.00 |
Risks flagged
CFO transition risk
“Departure of CFO and appointment of interim CFO; Duckworth has prior company experience reducing risk”
25 Mar 2026DEF 14ARevenue $3.22B; Net Income (Loss) $-1.10B; Adjusted EBITDA $612M (-14% y/y)open
Figures in the filing · each found in the filing text
| Revenue · FY2025 | $3.22B | |
| Net Income (Loss) · FY2025 | $-1.10B | |
| Adjusted EBITDA · FY2025 | $612M | -14% y/y |
| Bed Count · FY2025 | 12,500 | |
| Facility Count · FY2025 | 277 | |
| Goodwill Impairment · FY2025 | $996M | |
| Legal Settlements Expense · FY2025 | $151M |
Risks flagged
Litigation Risk
“Legal settlements expense (d) 150,966” · word for word
Goodwill Impairment Risk
“the amount for the year ended December 31, 2025 includes a non-cash goodwill impairment charge of $996.2 million.” · word for word
Regulatory/Government Investigation Risk
“Transaction, legal and other costs (b) 163,630” · word for word
12 Mar 20268-K · 5.02, 7.01Reported the departure of a director or principal officer (CEO/CFO change); issued a Regulation FD disclosure (forward guidance or material update)open
Risks flagged
No material risk; board transition is routine.
“No disagreement with company; no material changes to operations.”
27 Feb 202610-KRisks named: Medicaid/ACA policy risk, High leverage risk, Labor cost inflationopen
Risks flagged
Medicaid/ACA policy risk
“The OBBBA reduces federal Medicaid expenditures and tightens beneficiary eligibility requirements... marketplace premiums have increased substantially, and enrollment for the 2026 plan year declined significantly.” · word for word
High leverage risk
“At December 31, 2025, we had approximately $2.5 billion of total debt” · word for word
Labor cost inflation
“A shortage of nurses, qualified addiction counselors and other medical and care support personnel... has been a significant operating issue” · word for word
25 Feb 20268-K · 2.02, 7.01Released earnings results and quarterly financials; issued a Regulation FD disclosure (forward guidance or material update)earningsopen
Risks flagged
OBBBA introduces work requirements for Medicaid expansion, potentially reducing patient volumes and revenue.
“OBBBA’s introduction of work or community engagement requirements in the Medicaid expansion population” · word for word
Integration risk from acquisitions and facility expansions.
“potential difficulties in successfully integrating the operations of acquired facilities” · word for word
Litigation and regulatory actions could impact stock price and operations.
“occurrence of patient incidents, governmental investigations, litigation and adverse regulatory actions” · word for word
23 Jan 20268-K · 5.02Retention bonus cash payment $2Mopen
Figures in the filing · each found in the filing text
| retention bonus cash payment · 2026 | $2M |
Risks flagged
CEO departure creates leadership uncertainty and potential strategic disruption.
“CEO Christopher Hunter departed effective January 20, 2026; separation agreement includes significant cash payments.”
20 Jan 20268-K · 5.02, 7.01CEO base salary $1Mopen
Figures in the filing · each found in the filing text
| CEO base salary · FY2026 | $1M |
Risks flagged
Leadership transition risk; new CEO may implement strategic changes.
“New CEO appointment with employment agreement.”
2 Dec 20258-K · 7.01Adjusted EBITDA guidance $601M; Adjusted EPS guidance $1.94; PLGL expense $116M (+115% y/y); Guidance: Adjusted EBITDA reduced by $49M to $601-611M; EPS reduced by $0.41 to $1.94-2.04open
Figures in the filing · each found in the filing text
| Adjusted EBITDA guidance · FY2025 | $601M | |
| Adjusted EPS guidance · FY2025 | $1.94 | |
| PLGL expense · FY2025 | $116M | +115% y/y |
| Net PLGL liability at year-end 2025 · FY2025 | $145M | |
| PLGL expense 2026 guidance · FY2026 | $100M |
Guidance
Adjusted EBITDA reduced by $49M to $601-611M; EPS reduced by $0.41 to $1.94-2.04
Guidance cut driven entirely by PLGL expense increase; no demand or revenue weakness indicated.
Risks flagged
Litigation liability pressure: patient-related claims driving significant PLGL expense increase; 168% claim frequency increase; less favorable reinsurance.
“Higher expected settlement costs for claims related to policy years prior to September 1, 2024; A 168% increase in claim frequency during the 2025 policy year; Less favorable reinsurance coverage terms versus prior years.” · word for word
10 Nov 20258-K · 7.01Acadia Healthcare agreed to settle securities litigation for $179M, with $30M expected from insurance. Settlement has no impact on adjusted EBITDA or financial guidance. Company maintains strong liquidity with $118.7M cash and $786.7M revolopen
Figures in the filing · each found in the filing text
| Cash and cash equivalents · Q3-2025 | $119M | |
| Revolving credit facility availability · Q3-2025 | $787M | |
| Consolidated Total Net Leverage Ratio · Q3-2025 | $3.40 |
Guidance
Settlement has no impact on previously announced financial guidance; company affirms strong financial position.
Risks flagged
Securities litigation settlement of $179M creates a material cash outflow, though partially offset by insurance and strong liquidity.
“Acadia agreed to pay an aggregate amount of $179 million as the monetary component of the settlement.” · word for word
5 Nov 202510-QRevenue $852M (+4% y/y); Net income attributable to Acadia $36M (-47% y/y); Bed count 12,500open
Figures in the filing · each found in the filing text
| Revenue · Q3-2025 | $852M | +4% y/y |
| Net income attributable to Acadia · Q3-2025 | $36M | -47% y/y |
| Bed count · 2025-09-30 | 12,500 | |
| Facility count · 2025-09-30 | 278 | |
| Same facility revenue growth · Q3-2025 | 3.7% | |
| Same facility patient days growth · Q3-2025 | 1.3% | |
| Operating cash flow · 9M-2025 | $218M | +1578% y/y |
| Cash and cash equivalents · 2025-09-30 | $119M |
Risks flagged
Elevated legal and investigation costs
“Government investigation costs $38.7M in Q3 2025 vs $3.1M in prior year.”
Labor cost pressure
“SWB as % of revenue increased from 51.3% to 53.6%.”
Medicaid policy changes
“OBBBA includes restrictions on provider tax arrangements starting 2028.”
5 Nov 20258-K · 2.02, 5.02Revenue $852M (+4% y/y); Same facility revenue growth 3.7; Patient days growth 1.3; Guidance: Revenue guidance lowered to $3.28-3.30B from $3.30-3.35B; Adjusted EBITDA to $650-660M from $675-700M; Adjusted EPS to $2.35-2.45 from $2.45-2.65earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q3-2025 | $852M | +4% y/y |
| Same facility revenue growth · Q3-2025 | 3.7% | |
| Patient days growth · Q3-2025 | 1.3% | |
| Net income attributable to Acadia · Q3-2025 | $36M | -46% y/y |
| Adjusted EBITDA · Q3-2025 | $173M | -11% y/y |
| Adjusted income attributable to Acadia · Q3-2025 | $65M | -21% y/y |
| Revenue guidance · FY2025 | $3.29B |
Guidance
Revenue guidance lowered to $3.28-3.30B from $3.30-3.35B; Adjusted EBITDA to $650-660M from $675-700M; Adjusted EPS to $2.35-2.45 from $2.45-2.65
Lowered full-year guidance due to volume/rate pressure, bad debt, and PLGL costs; reducing capex to improve free cash flow.
Risks flagged
Persistent volume and rate pressure from Medicaid and payor scrutiny.
“Persistent softness in acute care Medicaid volumes and heightened payor scrutiny around authorizations.” · word for word
Elevated bad debt and denials expected to continue in Q4.
“Revenue was negatively impacted by elevated levels of bad debt and denials, which are expected to remain a headwind in the fourth quarter.” · word for word
Higher PLGL costs with incremental $4-6M expected in Q4.
“Revised outlook incorporates an incremental assumption on PLGL charges of $4.0 million to $6.0 million that are now expected in the fourth quarter.” · word for word
Startup losses from new facilities increasing.
“Startup losses from newly opened facilities totaled $13.3 million in the quarter, up from $7.3 million in the third quarter of 2024.” · word for word
Acadia Healthcare Company, Inc. — questions
- What did Acadia Healthcare Company, Inc. file recently?
- 20 SEC filings in the last 12 months. Latest: 8-K on 2026-09-25 — Acadia Healthcare disclosed preliminary approval of a settlement in stockholder derivative actions related to previously settled securities litigation. The settlement is subject to final court approval.
Every figure on this page comes from Acadia Healthcare Company, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.